China News Service, January 18th (Zuo Yuqing, Zhongxin Finance) On the 18th, Zhongxin Finance learned from the press conference on the adjustment of the National Medical Insurance Drug Catalog in 2022 that the 2022 National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog The adjustment work has now been successfully completed.
According to the National Medical Insurance Administration, the national medical insurance negotiations fully support the treatment of new coronavirus infection.
For the third consecutive year, new crown treatment drugs have been included as a condition for admission to the national medical insurance catalog.
Two drugs, including Azivudine Tablets and Qingfei Paidu Granules, will be officially included in the national medical insurance catalog after price reductions through negotiations
.
Among the 25 marketed drugs involved in the tenth edition of the new coronavirus infection diagnosis and treatment plan, 21 varieties have been officially included in the national medical insurance catalog.
In addition, the national medical insurance negotiations continue to support the entry of drugs in key areas into the list.
Support domestically produced major innovative drugs to be included in the catalog. This time, a total of 24 domestically produced major innovative drugs were included in the negotiations, and finally 20 drugs such as Orebatinib were successfully negotiated.
At the same time,
7 drugs for rare diseases, 22 drugs for children, and 2 essential drugs have been successfully included in the catalog
, and the level of drug protection in key areas has been further improved.
(Finish)